Drug-resistance of gonorrhoea in the EU: persistent but stable

04 September 2018

Article: 52/3503

According to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area. This threatens the effectiveness of the currently recommended dual therapy regimen for gonorrhoea. Overall, the rates of resistance to cefixime, ceftriaxone and azithromycin have remained stable when compared to recent years.

Euro-GASP aims to strengthen the surveillance of gonococcal antimicrobial susceptibility in EU/EEA Member States in order to provide quality-assured data to inform gonorrhoea treatment guidelines. This report presents the results from the 2016 gonococcal antimicrobial susceptibility sentinel surveillance.

Source: ECDC, 30 August 2018